Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Two new series of PDE5 inhibitors claimed by Pfizer

May 19, 2000

New class of peptides useful as selective alpha1-adrenoceptor antagonists

May 18, 2000

FDA requests additional animal data for Vasomax

May 18, 2000

HCT-1026 enters phase II trials for overactive bladder

May 15, 2000

Tanabe Seiyaku patents new inhibitors of PDE5

May 15, 2000

Fujisawa's new oxazole compounds particularly useful for glomerulonephritis

May 15, 2000

Sanofi-Synthelabo designs new PDE5 inhibitors, as reported in recent patent

May 12, 2000

A-204176 may increase IUP without cardiovascular side effects according to preclinical data

May 5, 2000

Early clinical trial results in BPH suggest promise of new highly selective alpha1A blocker

May 5, 2000

Profile of KUL-7211, a new beta-adrenoceptor agonist with selectivity for ureteral smooth muscle

May 5, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...